Capstone Holding Corp. lowers convertible note conversion price to $1.00
Silexion Therapeutics Corp (NASDAQ:SLXN) announced Monday that shareholders approved all proposals at its reconvened 2025 annual general meeting after an initial adjournment on July 7 due to lack of quorum. The information is based on a press release statement filed with the SEC.
At the meeting, holders of approximately 12.1% of the company’s outstanding ordinary shares were present in person or by proxy. In line with the company’s articles of association, the shareholders present constituted a quorum after a half-hour elapsed from the meeting’s start.
Shareholders elected Ilan Hadar, Dror J. Abramov, Ruth Alon, Ilan Levin, Avner Lushi, Shlomo Noy, and Amnon Peled to the board of directors. The vote counts for directors ranged from 68.1% to 97% in favor, with the remainder voting against or abstaining.
The meeting also ratified the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Limited, as the company’s independent public accountants for the year ending December 31, 2025. This proposal was approved by 98.3% of votes cast, with 1.7% against and 4,864 abstentions.
Shareholders authorized the board to implement a reverse share split of the company’s ordinary shares at a 1-for-15 ratio. This measure was approved by 59.6% of votes cast, with 40.4% opposed and 2,593 abstentions.
In addition, shareholders approved an increase in the number of ordinary shares reserved for issuance under the company’s 2024 Equity Incentive Plan by 1,271,859 shares, bringing the total to 1,428,268 ordinary shares. This number will be adjusted downward proportionally if the reverse split is executed. The proposal received 58.3% of votes in favor, 41.7% against, and 127,351 abstentions.
Silexion Therapeutics’ ordinary shares and related warrants continue to be listed on The Nasdaq Stock Market LLC under the symbols SLXN and SLXNW, respectively.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.